Spero Therapeutics, Inc.
SPRO
$2.38
-$0.05-2.06%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 39.15% | -36.61% | -79.54% | -47.12% | 275.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 39.15% | -36.61% | -79.54% | -47.12% | 275.44% |
| Cost of Revenue | -55.02% | -21.50% | 87.14% | 13.57% | 149.47% |
| Gross Profit | 126.00% | 4.13% | -359.15% | -48.64% | -99.12% |
| SG&A Expenses | 6.24% | 15.33% | 9.68% | -8.93% | -9.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.43% | -12.13% | 56.12% | 45.07% | 87.48% |
| Operating Income | 87.61% | -4.11% | -141.26% | -651.39% | -47.87% |
| Income Before Tax | 90.48% | -9.45% | -139.94% | -1,654.23% | -49.92% |
| Income Tax Expenses | -- | -- | -25.06% | -113.12% | -- |
| Earnings from Continuing Operations | 90.48% | -9.45% | -140.80% | -435.01% | -49.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 90.48% | -9.45% | -140.80% | -435.01% | -49.92% |
| EBIT | 87.61% | -4.11% | -141.26% | -651.39% | -47.87% |
| EBITDA | 87.62% | -4.79% | -141.23% | -634.28% | -49.12% |
| EPS Basic | 90.85% | -5.79% | -139.65% | -421.05% | -46.07% |
| Normalized Basic EPS | 91.30% | -4.46% | -137.16% | -494.13% | -46.12% |
| EPS Diluted | 90.85% | -5.79% | -139.87% | -421.05% | -46.07% |
| Normalized Diluted EPS | 91.30% | -4.46% | -137.23% | -494.13% | -46.12% |
| Average Basic Shares Outstanding | 3.83% | 3.46% | 2.90% | 2.68% | 2.64% |
| Average Diluted Shares Outstanding | 3.83% | 3.46% | 2.69% | 2.68% | 2.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |